MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Status:
Completed
Trial end date:
2017-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study is to determine whether treatment with MEK162
demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic
malignancies to warrant further study